Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 satoreotide tetraxetan - Ariceum Therapeutics

Next Previous
Drug Profile

Lutetium-177 satoreotide tetraxetan - Ariceum Therapeutics

Alternative Names: 177Lu-DOTA- JR11; 177Lu-IPN01072; 177Lu SSO 110; 177Lu-IPN-1072; 177Lu-OPS 201; 177Lu-satoreotide; [177Lu]LuSSO110; Lutetium-177-DOTA-satoreotide; SOMther®

Latest Information Update: 13 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OctreoPharm Sciences
  • Developer Ariceum Therapeutics; Ipsen
  • Class Antineoplastics; Drug conjugates; Peptides; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours
  • Phase I Small cell lung cancer
  • Phase 0 Meningioma
  • Preclinical Merkel cell carcinoma

Most Recent Events

  • 13 Jun 2024 Lutetium-177 satoreotide tetraxetan is still in phase-0 development in Meningioma(Late-stage disease, Second-line therapy or greater) in Switzerland (NCT04997317)
  • 10 Jun 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Ariceum Therapeutics
  • 28 May 2024 No recent reports of development identified for phase-0 development in Meningioma(Late-stage disease, Second-line therapy or greater) in Switzerland (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top